The APMAP Knockout Jurkat Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population derived from the human Jurkat T lymphocyte line. This product provides a targeted disruption of the APMAP gene, resulting in a loss-of-function model that eliminates APMAP expression in a heterogeneous cell pool. The polyclonal format preserves the natural diversity of gene-editing outcomes, making it well suited for population-level functional studies without the constraints of clonal selection. These cells are supplied as a ready-to-use resource for advanced research applications.
Jurkat cells are an immortalized T-cell leukemia line widely used in immunology to study T-cell receptor signaling, apoptosis, and cytokine production. Their well-characterized pathways and robust growth make them ideal for CRISPR knockout studies. This background allows isolation of APMAP-specific functions in non-adipocyte contexts, such as T-cell adhesion and signaling.
APMAP encodes a transmembrane protein involved in adipocyte biology, where it integrates signals from PPARG and insulin to modulate adipogenesis, insulin sensitivity, and extracellular matrix (ECM) organization. Mechanistically, APMAP acts at the nexus of ECM and metabolic signaling: it interacts with ECM proteins and integrins, and influences downstream targets such as glucose transporter GLUT4, insulin receptor substrates, and lipid droplet proteins. Within the adipogenic cascade, APMAP is associated with transcription factors CEBPA and downstream effectors including FABP4 and ADIPOQ. This network positions APMAP as a key modulator of metabolic homeostasis linking structural cues to intracellular energy sensing.
In the Jurkat T-cell context, APMAP knockout offers a unique opportunity to delineate non-adipocyte roles of this protein. T lymphocytes do not execute endogenous adipogenic programs, so this model can reveal unexpected APMAP functions in cell adhesion, migration, or immune signaling that may be relevant to metabolic disease-associated immune dysregulation. The polyclonal knockout format enables population-level analyses, allowing assessment of heterogeneous cellular responses. This configuration is particularly useful for pathway-level studies where bulk measurements such as Western blotting, flow cytometry, or metabolic assays are employed, and it provides a complementary platform to adipocyte-focused research.
Applications include studying APMAP function in T-cell biology, investigating adipocyte pathways in a non-adipocyte setting, and drug screening for obesity and type 2 diabetes. Compatible assays are RT-qPCR, Western blotting, flow cytometry, cell adhesion, migration, and metabolic assays, enabling thorough characterization. For more information, contact Ascent Research.
